Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.40 |
| ▸ | MAG | P20916 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14944651 | 0.89 | CASP1 (0.43) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL25702221 | 0.84 | MAG (0.52) | NANPMAG | |
| SCHEMBL12473333 | 0.84 | MAG (0.52) | NANPMAG | |
| SCHEMBL31500844 | 0.84 | MAG (0.52) | NANPMAG | |
| SCHEMBL14946228 | 0.84 | MAG (0.52) | NANPMAG | |
| SCHEMBL14229129 | 0.84 | MAG (0.52) | NANPMAG | |
| SCHEMBL27977966 | 0.84 | MAG (0.52) | NANPMAG | |
| SCHEMBL27909377 | 0.74 | NANP (0.65) | NANPMAG | |
| SCHEMBL20968002 | 0.73 | NANP (0.61) | NANPMAG | |
| SCHEMBL14902803 | 0.73 | NANP (0.61) | NANPMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889607-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889607-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-2771348-B1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200131215-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200131215-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. | 2020-04-30 | — | — | US | disclosed |
| US-10457701-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457701-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190127409-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. | 2019-05-02 | — | — | US | disclosed |
| US-20190127409-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. | 2019-05-02 | — | — | US | disclosed |
| US-10065981-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20160297846-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9221858-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221858-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150038693-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038693-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8840926-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8840926-B2 | Sialic acid analogs | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130122094-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122094-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013063149-A1 | SIALIC ACID ANALOGS | ULTRAGENYX PHARMACEUTICAL, INC. (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457701-B2 | Sialic acid analogs | NEU1, NEU2, NEU3 | NANP 37/4885CASP1 4712/4885CASP3 4746/4885 |
| US-20200131215-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | NANP 37/4885CASP1 4712/4885CASP3 4746/4885 |
| US-10065981-B2 | Sialic acid analogs | NEU1, NEU2, NEU3 | NANP 37/4885CASP1 4712/4885CASP3 4746/4885 |
| US-20160297846-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | NANP 37/4885CASP1 4712/4885CASP3 4746/4885 |
| US-20130122094-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | NANP 37/4885CASP1 4712/4885CASP3 4746/4885 |
| US-20150038693-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | NANP 37/4885CASP1 4712/4885CASP3 4746/4885 |
| US-10889607-B2 | Sialic acid analogs | NEU1, NEU2, NEU3 | NANP 37/4885CASP1 4712/4885CASP3 4746/4885 |
| US-20190127409-A1 | SIALIC ACID ANALOGS | NEU1, NEU2, NEU3 | NANP 37/4885CASP1 4712/4885CASP3 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.